About 589 million adults lived with diabetes worldwide in 2024.
Why this market is moving now
- Adults living with diabetes are projected to rise to 853 million by 2050.
- About 252 million people live with diabetes that has not been diagnosed.
- Abbott won US approval in 2026 for Libre Duo, a sensor that reads both glucose and ketones.
Key figures
Global figures for this market, with the year each one describes. Use Cite to copy a reference to this page.
| Figure | Value | Year | Cite |
|---|---|---|---|
| Dexcom's worldwide revenue grew 16% to $4.662 billion in 2025. | 4.662 USD billion | 2025 | |
| Dexcom's revenue grew 11% to $1.344 billion in the third quarter of 2026, with US revenue up 14% and international revenue up 5%. | 1.344 USD billion | 2026 | |
| Dexcom expects 2026 revenue of $5.20 billion to $5.25 billion, about 12% to 13% growth. | 5.20-5.25 USD billion (company guidance) | 2026 | |
| Abbott's worldwide sales of continuous glucose monitors were $2.0 billion in the fourth quarter of 2025, up 15.0%. | 2.0 USD billion | 2025 | |
| Abbott's continuous glucose monitor sales grew 7.3% in the third quarter of 2026, a quarter in which it won US approval for its Libre Duo glucose and ketone sensor. | 7.3 % growth | 2026 | |
| Abbott's worldwide Diabetes Care sales were $2,185 million in the third quarter of 2026, of which $1,313 million came from outside the US. | 2,185 USD million | 2026 | |
| MiniMed's net sales grew 17% to $843 million in the quarter to 31 July 2026. | 843 USD million | 2026 | |
| About 589 million adults aged 20 to 79 were living with diabetes worldwide in 2024. | 589 million adults | 2024 | |
| The number of people living with diabetes worldwide is projected to reach 853 million by 2050. | 853 million people (projection) | 2050 | |
| About 252 million people worldwide live with diabetes that has not been diagnosed. | 252 million people | 2024 |
Calculated figures (shares, changes and prices per kilogram) are plain arithmetic on the reported values. Read how we work.
Companies to watch
Dexcom
Continuous glucose monitor maker with 2025 revenue of $4.662 billion.
Abbott
Maker of Libre glucose sensors; CGM sales were $2.0 billion in Q4 2025.
MiniMed
Insulin pump and sensor maker with net sales of $843 million in the quarter to 31 July 2026.
What the full report covers
- 01Executive summary
The answer in one page: size, direction and what moves it - 02Market definition and scope
What is in and out of the global market - 03Global market size, 2021 to 2025
Historical series and growth rates - 04Countries and regions
Demand, supply and trade by country and region - 05Outlook to 2031
Base, low and high scenarios with stated assumptions - 06Rules, policy and deadlines
Regulation and programmes that change demand - 07Drivers and barriers
What accelerates or slows adoption, by customer segment - 08Prices, costs and margins
Unit economics where public data allows - 09Competitive landscape
8 to 12 company profiles with recent moves - 10Opportunities and risks
For new entrants, suppliers and investors - 11Method and assumptions
How every figure was built
Included with the full report
- PDF report, 40 to 60 pages
- Excel data pack
- Ready-to-use charts
- Method note and assumptions
- Written to order in 5 working days
Frequently asked questions
How big is the global CGM market?
Dexcom's revenue was $4.662 billion in 2025. Abbott sold $2.0 billion of continuous glucose monitors in the fourth quarter of 2025 alone.
Which companies make the most continuous glucose monitors?
Dexcom had 2025 revenue of $4.662 billion. Abbott sold $2.0 billion of CGMs in Q4 2025. MiniMed, which sells pumps and sensors, had net sales of $843 million in the quarter to 31 July 2026.
How fast is the CGM market growing?
Dexcom revenue grew 11% in Q3 2026. Abbott's CGM sales grew 7.3% in the same quarter. MiniMed's net sales grew 17% in the quarter to 31 July 2026.
How many people could use a CGM?
About 589 million adults lived with diabetes worldwide in 2024, and about 252 million people have diabetes that has not been diagnosed.
What is the outlook for CGM demand?
Dexcom expects 2026 revenue of $5.20 to $5.25 billion. People living with diabetes are projected to reach 853 million by 2050.
How much does Abbott sell in diabetes care?
Abbott's Diabetes Care sales were $2,185 million in Q3 2026, with $1,313 million from outside the US.
Free sample
Get a free sample of this report
We send the table of contents, two sample chapters and the method note, usually within one working day. It is free to ask.
- Full table of contents
- Two sample chapters
- Method note and data outline